A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

NCT07717411 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1600

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer's Disease

Interventions

DRUG: Trontinemab
DRUG: Placebo

Sponsor

Hoffmann-La Roche